Life Sciences Intellectual Property Review

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#6641349

United States

#3672819

Law and Government/Legal

#16014

Traffic sources

Monthly visitors

Articles

USPTO: AI-inventions ‘not categorically unpatentable’

Jan 24, 2024 | lifesciencesipreview.com | Sarah Speight

Poptika / Shutterstock.comUS Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer| Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Federal Circuit rejects Cellect rehearing on double patenting

Jan 22, 2024 | lifesciencesipreview.com | Marisa Woutersen

Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis. To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription. If you are already subscribed please login.
Pharma body attacks ‘vague’ march-in rights plan

Dec 18, 2023 | lifesciencesipreview.com | Marisa Woutersen

Trevor Collens / ShutterstockPhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal. Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
Pharma industry pushes back on Biden’s ‘dangerous’ plan

Dec 11, 2023 | lifesciencesipreview.com | Marisa Woutersen

Luca Perra / Shutterstock.comThe Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation. Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.
USPTO hands win to Daiichi Sankyo in cancer drug dispute

Nov 29, 2023 | lifesciencesipreview.com | Marisa Woutersen

Pavel Kapysh / Shutterstock.comThe office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals. Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.
Regeneron prevails in eye treatment dispute and immediately launches

Nov 22, 2023 | lifesciencesipreview.com | Marisa Woutersen

Lev Radin / Shutterstock.comDistrict judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents. Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.
10x Genomics awarded $31m in key ruling over NanoString

Nov 20, 2023 | lifesciencesipreview.com | Marisa Woutersen

Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis. To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription. If you are already subscribed please login.
Cancer specialist to pay $83.4m over DNA sequencing infringement

Nov 15, 2023 | lifesciencesipreview.com | Marisa Woutersen

Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis. To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription. If you are already subscribed please login.
Saxton & Stump adds senior tech counsel

Nov 15, 2023 | lifesciencesipreview.com | Marisa Woutersen

Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis. To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription. If you are already subscribed please login.
Neurocrine resolves dispute over Huntington's treatment

Nov 13, 2023 | lifesciencesipreview.com | Marisa Woutersen

Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis. To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription. If you are already subscribed please login.